-
1.发明公开公开(公告)号：US20230340100A1
公开(公告)日：2023-10-26
申请号：US18320162
申请日：2023-05-18
申请人： UNIVERSITAT ZURICH
发明人： Burkhard BECHER , Sonia TUGUES
CPC分类号： C07K16/243 , A61P37/06 , C07K16/2866 , A61P35/02 , A61K2039/505
摘要： Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.
-
公开(公告)号：US20230146949A1
公开(公告)日：2023-05-11
申请号：US17913627
申请日：2021-03-25
申请人： UNIVERSITAT ZURICH
发明人： Andrea GUIDOTTI , Boaz HARARI , Luca VICENTINI , Pietro GOZZOLI
CPC分类号： A61B17/12136 , A61B17/12122 , A61M25/10182 , A61B2017/12095 , A61M2025/1054 , A61M2025/1068
摘要： A delivery system (10, 110) is provided for delivering and deploying an implantable balloon-based occlusion device (20) including an inflatable balloon (22). The delivery system (10, 110) includes a delivery handle (11), which includes a fluid-retaining chamber (41, 141); a plunger, which is slidingly disposed in the fluid-retaining chamber (41, 141); and a proximal rotatable user-control knob (31). A fluid-conveyance lumen catheter (18) defines a catheter fluid-conveyance lumen (19) in fluid communication with the fluid-retaining chamber (41, 141) and the inflatable balloon (22). A catheter lumen shaft (26) is in reversible connection with the balloon-based occlusion device (20), longitudinally slidable with respect to the delivery handle (11). The delivery handle (11) is configured such that rotation of the proximal rotatable user-control knob (31) in a first rotational direction concurrently (a) expels at least some of the fluid from the fluid-retaining chamber (41, 141) into the inflatable balloon (22), via the catheter fluid-conveyance lumen (19), and (b) shortens a length of the balloon-based occlusion device (20) by proximally pulling the catheter lumen shaft (26). Other embodiments are also described.
-
公开(公告)号：US20230028910A1
公开(公告)日：2023-01-26
申请号：US17789340
申请日：2020-11-13
申请人： SCAILYTE AG , UNIVERSITAT ZURICH
发明人： Peter NESTOROV , Vijay Kumar TIWARI , Manfred CLAASSEN , Philip KNUCKLES , Sarah HAMILTON CARL , Emmanuella GUENOVA , Christina FASSNACHT , Eleni Maria VARYPATAKI
IPC分类号： G01N33/50 , G01N33/574 , G01N33/49 , G01N33/563 , G16H50/30
摘要： The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.
-
公开(公告)号：US20220339250A1
公开(公告)日：2022-10-27
申请号：US17849643
申请日：2022-06-26
摘要： The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
-
公开(公告)号：US20220178497A1
公开(公告)日：2022-06-09
申请号：US17429027
申请日：2020-02-07
申请人： Universitat Zurich
发明人： Dominik Biscette , Johan Chang , Denys Sutter
IPC分类号： F17C3/08
摘要： A cryostat for operation with liquid helium, may comprise a primary chamber with a main region and a pot region for containing a bath of liquid helium-4, primary inlet means for introducing liquid helium-4 and primary outlet means for releasing gaseous helium-4, the primary inlet means comprising a transfer line extending into the primary region. The cryostat may be configured for operation under a continuous supply of liquid helium-4 and at a reduced helium-4 pressure, whereby gaseous helium-4 is pumped off through the outlet means. The primary chamber may comprise a baffle structure arranged between the pot region and the main region, the baffle structure defining at least one flowpath for the flow of gaseous helium-4, each flowpath forming a detoured connection between the pot region and the main region.
-
公开(公告)号：US11279747B2
公开(公告)日：2022-03-22
申请号：US16323902
申请日：2017-08-09
摘要： The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors.
Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.-
公开(公告)号：US11151739B2
公开(公告)日：2021-10-19
申请号：US16327871
申请日：2017-08-24
申请人： UNIVERSITAT ZURICH
IPC分类号： G06T15/06 , G06T7/579 , G06T7/73 , H04N13/271 , H04N13/111 , H04N13/282 , G06T15/08 , G06T15/20
摘要： The invention relates to a method for 3D reconstruction of a scene, wherein an event camera (1) is moved on a trajectory (T) along the scene, wherein the event camera (1) comprises a plurality of pixels that are configured to only output events (ek) in presence of brightness changes in the scene at the time (tk) they occur, wherein each event comprises the time (tk) at which it occurred, an address (xk,yk) of the respective pixel that detected the brightness change, as well as a polarity value (pk) indicating the sign of the brightness change, wherein a plurality of successive events generated by the event camera (1) along said trajectory (T) are back-projected according to the viewpoint (P) of the event camera (1) as viewing rays (R) through a discretized volume (DSI) at a reference viewpoint (RV) of a virtual event camera associated to said plurality of events, wherein said discretized volume (DSI) comprises voxels (V′), and wherein a score function ƒ(X) associated to the discretized volume (DSI) is determined, which score function ƒ(X) is the number of back-projected viewing rays (R) that pass through the respective voxel (V′) with center X, and wherein said score function ƒ(X) is used to determine whether or not a 3D point of the 3D reconstruction of the scene is present in the respective voxel (V′).
-
公开(公告)号：US10901055B2
公开(公告)日：2021-01-26
申请号：US15573881
申请日：2016-05-11
摘要： A magnetic resonance (MR) system comprises a main magnetic field and an RF power amplifier for generating an RF field in a first RF band, the arrangement further comprising at least one magnetic field probe (2), said magnetic field probe comprising a MR active probe substance, means for pulsed MR excitation of said probe substance (4) in a second RF band and means for receiving a probe MR signal in the second RF band generated by said probe substance. In order to improve performance of the system, the latter comprises means for recording the output signal of the RF power amplifier in said second RF band, and means for subtracting from said probe MR signal an interfering signal contribution contained in said recorded RF amplifier output signal.
-
公开(公告)号：US20190247466A1
公开(公告)日：2019-08-15
申请号：US16083508
申请日：2017-03-07
CPC分类号： A61K38/1774 , A61P35/00 , A61P37/02 , C07K14/70539 , C07K2319/30
摘要： The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents.Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
-
公开(公告)号：US20190241971A1
公开(公告)日：2019-08-08
申请号：US16341907
申请日：2017-10-13
申请人： UNIVERSITAT ZURICH
发明人： Irina BANZOLA , Maurizio PROVENZANO
IPC分类号： C12Q1/6886 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , G01N33/57434 , G01N2800/50 , G01N2800/54 , G01N2800/56
摘要： The invention relates to a method to predict a patient's risk of developing prostate cancer, or to distinguish indolent vs. aggressive cancers among patients suspected of bearing PCa and therefore selected for biopsy, and/or predict the risk of progression of prostate cancer in a patient having undergone prostate cancer treatment, particularly by radical prostatectomy, brachytherapy, and/or external beam radiation therapy, wherein said method comprises detecting/quantifying the level of indoleamine-2,3-dioxygenase (IDO) mRNA or protein in a urine sample obtained from said patient.
-
-
-
-
-
-
-
-
-
搜索结果
200 条记录 (耗时 0.028 秒)
